Navigation Links
GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting

in the Phase III ADT clinical trial.

-- "Prevalence of osteoporosis and osteopenia during androgen deprivation therapy (ADT) for prostate cancer: Baseline data from a large randomized controlled trial." Poster number: F5. Abstract number: 5116.

-- Date and time: June 3, 2007 from 2:00 to 6:00 p.m.

-- Location: S Hall A2

About GTx

GTx, headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways to treat cancer, osteoporosis and bone loss, muscle wasting and other serious medical conditions. GTx is developing ACAPODENE(R) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN. GTx has licensed to Ipsen Limited exclusive rights in Europe to develop and commercialize ACAPODENE(R). GTx also is developing Ostarine(TM), a first-in-class selective androgen receptor modulator, or SARM. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for cancer cachexia in non-small cell lung cancer patients in June of 2007. GTx plans to initiate a Phase IIb Ostarine(TM) clinical trial for the treatment of chronic kidney disease muscle wasting by the end of 2007. GTx believes that Ostarine(TM) also has the potential to treat a variety of other indications associated with muscle wasting and bone loss including sarcopenia and osteoporosis.

Forward-Looking Information is Subject to Risk and Uncertainty

This press release contains forward-looking statements based upon GTx's current expectations. Forward-looking statements involve risks and uncertaint
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:8/19/2014)... , Aug. 19, 2014  AVIA – a ... task on the biggest problems in healthcare ­– announces ... Northern California , as the most recent addition ... Health will participate in AVIA,s inaugural cohort focused helping ... care and transparency among a patient,s providers so they ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
(Date:8/19/2014)... , Aug. 19, 2014 ... Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today ... Annual Meeting of the American Academy of ... Care Surgery in Philadelphia, Pennsylvania ... The presentation will report results from a recently ...
Breaking Medicine Technology:AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3
... NEW YORK, Oct. 31 A recent outbreak ... to,as "the superbug," should cause organizations and facilities ... The superbug is resistant to common antibiotics. ... abscesses, boils and other pus-filled,lesions. Superbug infections prior ...
... Oct. 31 United,Therapeutics Corporation (Nasdaq: UTHR ... today that they will release the results of ... formulation of treprostinil,in pulmonary arterial hypertension (PAH) before ... Therapeutics will expand its previously scheduled conference,call on ...
Cached Medicine Technology:'Superbug' Outbreak Calls for Immediate Increased Attention on Infection Control 2Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007 2
(Date:8/20/2014)... IQ Formulations , a top national health ... Inc. 500 , distinguishing it as one of the fastest ... only made the list, but was ranked in the top ... three years. It also ranked ninth among all health companies, ... second fastest growing company in the Miami metro area. ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) ... AND DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the ... to grow to $15.2 billion by 2019, with ... 15.9%. Increasing industrialization is driving significant growth ... expanding range of industrial applications such as military ...
(Date:8/20/2014)... 2014 It’s no secret that millions ... the National Institute on Drug Abuse, nearly 24 million ... even more alarming is the fact that the total ... , Those locked in a struggle with substance abuse ... But now, the newly-redesigned AbuseTreatmentCenters.net has released updated lists ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... Awards. PM360, a leading health-marketing industry trade magazine, will ... 2009, the Trailblazer Awards are given to outstanding companies, ... has to offer. , “We are proud to ... our call to entries with double the number of ...
(Date:8/20/2014)... York, NY (PRWEB) August 20, 2014 ... world’s largest nutrition school, is proud to announce ... Integral Studies (CIIS), a cutting-edge university offering ... Nutrition’s Health Coach Training Program are now eligible ... of Arts in Integrative Health Studies. , “I’m ...
Breaking Medicine News(10 mins):Health News:Leading Health Supplement Company IQ Formulations Among Inc. Magazine’s Top 50 Fastest Growing Private Companies in the United States 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3
... cohort studies on the association of alcohol consumption with colorectal ... 2 from Australia, 13 from Western Europe, and 24 from ... least at higher levels of consumption, is associated with an ... was no increase in the risk for consumers reporting an ...
... , TUESDAY, Sept. 13 (HealthDay News) --The lifestyle changes ... disease may also improve sexual function in men with ... from the Mayo Clinic in Rochester, Minn., analyzed six ... determine how lifestyle changes and drugs used to treat ...
... for an effective vaccine and treatment against the potentially fatal ... the discovery of two ,Achilles, heels, within the virus. ... South Wales (UNSW) studied individuals at high risk of HCV ... the onset of infection. Using a new technique ...
... Canadian researchers has found the first evidence that lifelong ... While hearing studies have already shown that trained musicians ... is the first study to examine hearing abilities in ... 18 to 91 years of age. The study ...
... HealthDay Reporter , MONDAY, Sept. 12 (HealthDay News) -- ... become fathers, perhaps because they don,t need to compete with ... with their children. The findings don,t prove that fatherhood ... hormonal systems in men may detect that they,ve become fathers ...
... MONDAY, Sept. 12 (HealthDay News) -- Implantable electronic devices ... heart conditions and save lives, but these benefits may ... complications, a new study suggests. Researchers from the ... that people who develop an infection related to a ...
Cached Medicine News:Health News:Relation of alcohol consumption to colorectal cancer 2Health News:Breakthrough opens new avenues for hep C vaccine 2Health News:Science finding is music to the ears 2Health News:Testosterone Levels Seem to Fall With Fatherhood 2Health News:Testosterone Levels Seem to Fall With Fatherhood 3Health News:Heart Devices Like Pacemakers Linked to Infections 2
Inquire...
Superior Skin Care...Convex FlexWear skin barrier is secure and provides extended weartime. Security and confidence assured with internal non-reflux valves and a drain valve that allows regulation of...
Protects skin from corrosive drainage with the standard wear, FlexWear skin barrier. Security and confidence assured with porous tape, internal non-reflux valves, convenient drain valve....
Firstchoice drainable pouch with softflex skin barrier, cushionfit backing, transparent odor-barrier quiet film and microporous adhesive....
Medicine Products: